IDH2 and astrocytoma (excluding glioblastoma): Nevertheless, the present cohort of patients with IDH-mutant astrocytomas is relatively large and may serve as a framework for further efforts aiming at characterizing novel markers for improved prediction of therapy response and outcome that could also guide treatment strategy and clinical trial design, notably with the view to defining the role of IDH inhibitors along the disease trajectory [32].